title: Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Mayte
authors.initials: M
authors.lastname: Pérez-Olmeda
authors.forename: Pilar
authors.initials: P
authors.lastname: Ríos
authors.forename: Marina
authors.initials: M
authors.lastname: Núñez
authors.forename: Javier
authors.initials: J
authors.lastname: García-Samaniego
authors.forename: Juan
authors.initials: J
authors.lastname: González-Lahoz
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005838:Genotype; D006679:HIV Seropositivity / Q000150:complications* / Q000503:physiopathology; D016174:Hepacivirus / Q000235:genetics* / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D017093:Liver Failure / Q000209:etiology; D008111:Liver Function Tests; D012254:Ribavirin / Q000627:therapeutic use*; D012309:Risk-Taking; D015819:Substance Abuse, Intravenous / Q000150:complications*; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons